Researchers at the Gladstone Institute of Neurological Disease (GIND) have identified a potential target for Alzheimer's disease. They have determined in mouse models that modulating the activity of enkephalin peptides in the brain might reduce the cognitive deficits seen in Alzheimer's disease (AD). Enkephalins are part of the endogenous opioid system, which modulates learning and memory and other brain functions. They are produced by several different cell types in the brain, particularly in areas affected by AD.

Full story: newkerala.com